ReviewEye (London, England)2015
Advances in retinal ganglion cell imaging.
Review in Eye (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 46 citations in OpenAlex.
- Monitoring Gene Expression in Retina with synthetic serum markers.bioRxiv : the preprint server for biology · 2026Article
- Retinal ganglion cell vulnerability to pathogenic tau in Alzheimer's disease.Acta neuropathologica communications · 2025Article
- Review
- A Novel Retinal Nerve Fiber Layer Biomarker of Amyotrophic Lateral Sclerosis (ALS) Identified Using Longitudinal in vivo Ocular Imaging.Eye and brain · 2025Article
- Retinal ganglion cell vulnerability to pathogenic tau in Alzheimer's disease.bioRxiv : the preprint server for biology · 2024Article
- Characterizing Presumed Displaced Retinal Ganglion Cells in the Living Human Retina of Healthy and Glaucomatous Eyes.Investigative ophthalmology & visual science · 2024Article
- Comparison of Brn3a and RBPMS Labeling to Assess Retinal Ganglion Cell Loss During Aging and in a Model of Optic Neuropathy.Investigative ophthalmology & visual science · 2024Article
- Article
- Review
- Graphene-based microfluidic perforated microelectrode arrays for retinal electrophysiological studies.Lab on a chip · 2023Article
- Automatic counting of retinal ganglion cells in the entire mouse retina based on improved YOLOv5.Zoological research · 2022Article
- Prediction of visual field defects from macular optical coherence tomography in glaucoma using cluster analysis.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2022Article
- Tools and Biomarkers for the Study of Retinal Ganglion Cell Degeneration.International journal of molecular sciences · 2022Review
- Quantification of Retinal Ganglion Cell Morphology in Human Glaucomatous Eyes.Investigative ophthalmology & visual science · 2021Article
- The eye, the kidney, and cardiovascular disease: old concepts, better tools, and new horizons.Kidney international · 2020Review
- Article
- The Hub-and-Spoke Management of Glaucoma.Frontiers in neuroscience · 2020Review
- Suite of methods for assessing inner retinal temporal dynamics across spatial and temporal scales in the living human eye.Neurophotonics · 2020Article
- Midget retinal ganglion cell dendritic and mitochondrial degeneration is an early feature of human glaucoma.Brain communications · 2019Article
- In vivo imaging of adeno-associated viral vector labelled retinal ganglion cells.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is one of the leading causes of blindness worldwide and will affect 79.6 million people worldwide by 2020. It is caused by the progressive loss of retinal ganglion cells (RGCs), predominantly via apoptosis, within the retinal nerve fibre layer and the corresponding loss of axons of the optic nerve head. One of its most devastating features is its late diagnosis and the resulting irreversible visual loss that is often predictable. Current diagnostic tools require significant RGC or functional visual field loss before the threshold for detection of glaucoma may be reached. To propel the efficacy of therapeutics in glaucoma, an earlier diagnostic tool is required. Recent advances in retinal imaging, including optical coherence tomography, confocal scanning laser ophthalmoscopy, and adaptive optics, have propelled both glaucoma research and clinical diagnostics and therapeutics. However, an ideal imaging technique to diagnose and monitor glaucoma would image RGCs non-invasively with high specificity and sensitivity in vivo. It may confirm the presence of healthy RGCs, such as in transgenic models or retrograde labelling, or detect subtle changes in the number of unhealthy or apoptotic RGCs, such as detection of apoptosing retinal cells (DARC). Although many of these advances have not yet been introduced to the clinical arena, their successes in animal studies are enthralling. This review will illustrate the challenges of imaging RGCs, the main retinal imaging modalities, the in vivo techniques to augment these as specific RGC-imaging tools and their potential for translation to the glaucoma clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.